Phase1 Dose Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of ANAVEX2-73Dec 11, 2014CNS Summit 2014, Boca Raton, FLOle Voges, Ingo Weigmann, Norman Bitterlich, Christoph Schindler and Christopher MisslingView Poster
CNS Summit 2014, Boca Raton, FLOle Voges, Ingo Weigmann, Norman Bitterlich, Christoph Schindler and Christopher MisslingView Poster
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease
New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients